Suppr超能文献

特发性肺纤维化:诊断和管理的循证指南(美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布)

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

出版信息

Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.

Abstract

This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format. For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak). Recommendations were based on majority vote. It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.

摘要

本文件是关于特发性肺纤维化诊断和管理的国际循证指南,由美国胸科学会、欧洲呼吸学会、日本呼吸学会和拉丁美洲胸科协会共同制定。它代表了目前关于特发性肺纤维化(IPF)的知识状况,内容包括定义和流行病学、危险因素、诊断、自然史、分期和预后、治疗以及监测疾病过程。对于诊断和治疗部分,采用基于问题的实用 GRADE 循证方法学。对于每个诊断和治疗问题,委员会对现有证据的质量进行分级(高、中、低或极低),并提出建议(是或否,强或弱)。建议基于多数票。需要强调的是,临床医生必须与患者充分沟通,讨论患者的价值观和偏好,并决定适当的治疗方案。

相似文献

1
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
2
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.
5
The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications.
Respir Res. 2013;14 Suppl 1(Suppl 1):S2. doi: 10.1186/1465-9921-14-S1-S2. Epub 2013 Apr 16.
6
Managing diagnostic procedures in idiopathic pulmonary fibrosis.
Eur Respir Rev. 2013 Jun 1;22(128):158-62. doi: 10.1183/09059180.00001213.
7
Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study.
Lancet Respir Med. 2018 Nov;6(11):837-845. doi: 10.1016/S2213-2600(18)30286-8. Epub 2018 Sep 16.
10
Recommendations on treatment for IPF.
Respir Res. 2013;14 Suppl 1(Suppl 1):S6. doi: 10.1186/1465-9921-14-S1-S6. Epub 2013 Apr 16.

引用本文的文献

3
The Role of Particle Inhalation in Idiopathic Pulmonary Fibrosis.
Int J Mol Sci. 2025 Sep 8;26(17):8736. doi: 10.3390/ijms26178736.
6
Targeting E3 ubiquitin ligases: a new frontier in idiopathic pulmonary fibrosis treatment.
Front Immunol. 2025 Aug 18;16:1618424. doi: 10.3389/fimmu.2025.1618424. eCollection 2025.
7
Feasibility and acceptability of home-based pulmonary rehabilitation for individuals with idiopathic pulmonary fibrosis in Delhi, India.
Chron Respir Dis. 2025 Jan-Dec;22:14799731251375043. doi: 10.1177/14799731251375043. Epub 2025 Sep 3.

本文引用的文献

1
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease.
Eur Respir Rev. 2009 Jun;18(112):129-32. doi: 10.1183/09059180.00000409.
2
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
N Engl J Med. 2010 Aug 12;363(7):620-8. doi: 10.1056/NEJMoa1002110. Epub 2010 May 18.
3
A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis.
Eur Respir J. 2010 Nov;36(5):1067-72. doi: 10.1183/09031936.00152609. Epub 2010 Apr 22.
4
Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.
Intern Med. 2010;49(2):109-15. doi: 10.2169/internalmedicine.49.2359. Epub 2010 Jan 15.
5
Prognostic factors in rapidly progressive interstitial pneumonia.
Respirology. 2010 Feb;15(2):257-64. doi: 10.1111/j.1440-1843.2009.01687.x. Epub 2010 Jan 11.
6
Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.
Lung. 2010 Apr;188(2):115-23. doi: 10.1007/s00408-009-9209-8. Epub 2009 Dec 12.
7
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.
8
Pirfenidone in idiopathic pulmonary fibrosis.
Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8.
9
Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis.
Ann Intern Med. 2009 Dec 1;151(11):767-74. doi: 10.7326/0003-4819-151-11-200912010-00004.
10
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
Eur Respir J. 2010 Apr;35(4):830-6. doi: 10.1183/09031936.00155108. Epub 2009 Oct 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验